Aeglea BioTherapeutics (NASDAQ:AGLE) Rating Lowered to Equal Weight at Wells Fargo & Company

Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) was downgraded by investment analysts at Wells Fargo & Company from an “overweight” rating to an “equal weight” rating in a research note issued to investors on Wednesday, The Fly reports. AGLE has been the subject of a number of other research reports. HC Wainwright reiterated a “neutral” rating […]

Related Keywords

Aeglea Biotherapeutics ,Sphera Funds Management ,Wells Fargo Company ,Aeglea Biotherapeutics Inc ,Charles Schwab Investment Management Inc ,Get Rating ,Wells Fargo ,Point Capital Management ,Sigma Investments ,Funds Management ,Sigma Advisers ,Charles Schwab Investment Management ,Schwab Investment Management ,Nasdaq Agle ,Beagle ,Medical ,Downgrade ,